RT001 - Topical Botulinum Toxin Type A for the Treatment of Lateral Canthal Lines

The first application of the TransMTS™ technology is a topical botulinum toxin type A for the treatment of moderate to severe lateral canthal lines (crow's feet). RT001 is an investigational product in clinical stage development under an IND filed with the US FDA.

Clinical Results

RT001 demonstrated statistically significant efficacy versus placebo and achieved the primary and multiple secondary endpoints in the most recent US Phase 2b study. It appears to be safe and was well tolerated in over 200 patients in studies in the US and internationally. [View Press Release]

Baseline                                     Day 28 -                                                Post single treatment with RT001

Subject 006-006, Topical Botulinum Toxin Type A for the Treatment of Moderate to Severe Lateral Canthal Lines:
Preliminary Safety and Efficacy Results of a Blinded, Randomized, Placebo Controlled Trial,
Francisco Perez Atamoros, MD, Centros Dermatologicos Tennyson, Tennyson, Polanco, Mexico.

Expanding the Market

While botulinum toxin injections (Botox®) are the single largest aesthetic procedure performed in the US, up to 80% of Botox® Cosmetic usage is in the glabellar¹ (in between the eyebrows), where achieving the desired aesthetic benefit is less technique dependent. The crow's feet area (around the eyes) is of great consumer concern when it comes to aging, but this area has superficial musculature that tends to make injections more difficult, with an increased risk of adverse events (bruising, edema) and sub-optimal aesthetic results. RT001's topical application may allow physicians to achieve a more consistent result in superficial areas, without discomfort or bruising from needle injections.

At Revance, we believe that we can significantly expand the market by providing an attractive alternative to the current treatment options. A recent study by a leading consumer products company indicated up to 90% of the potential patient population would not use injectables due to needle aversion, pain and inconvenience. Eliminating needles and providing a superior consumer experience will lower the real and perceived barriers for those who are currently avoiding treatment. Additionally, company research indicates that even consumers who currently get injectable procedures would prefer a topical dose form.

¹ MEDACorp estimates and MedPanel Physician Survey, "Botox and Dermal Fillers" March 2007
BOTOX® is a registered trademark of Allergan, Incorporated